Medscreen is Europe’s leading dedicated provider of drug and alcohol testing services. Its customers include international maritime operators, UK occupational healthcare providers, and the UK criminal justice system, including Her Majesty’s Prisons. The company’s diagnostic laboratory is based in London, from where it also operates its international sample collection network.
Since Bowmark invested in March 2002, Medscreen has developed through both organic and acquisitive growth. Organic development has been driven by increased coverage of the international maritime fleet and by penetration of the UK workplace testing market as new sectors have increasingly adopted drug and alcohol testing practices. In addition, in March 2005 Medscreen successfully concluded the acquisition of its largest US competitor, Drug Testing International, to enhance its dominant position in the maritime sector.
With the increasing focus on workplace safety in industries such as transportation and oil & gas, Medscreen successfully expanded its drug testing services internationally
In the news
8 April 2021
Four acquisitions completed in Q1 2021 for Leaders Romans Group
22 March 2021
Bowmark-backed Totalmobile acquires workforce analytics provider Cognito iQ